Gemeinschaftspraxis Dr. Pourfard & Dr. Uleer
- Address
- lock Available on a paid plan
Gemeinschaftspraxis Dr. Pourfard & Dr. Uleer - Oncology Research Center
Gemeinschaftspraxis Dr. Pourfard & Dr. Uleer is a specialized oncology research center with extensive expertise in women's cancers, particularly focusing on advanced therapeutic interventions and precision medicine approaches. The center demonstrates particular strength in conducting complex Phase III clinical trials investigating novel targeted therapies and combination treatment strategies for breast and gynecological malignancies.
- Advanced ovarian, peritoneal, and fallopian tube cancer treatment with PARP inhibitors and anti-angiogenic agents
- Early and high-risk breast cancer research utilizing germline BRCA mutation testing and targeted adjuvant therapies
- Circulating tumor DNA (ctDNA) monitoring and precision endocrine therapy for hormone receptor-positive breast cancer
The research practice specializes in evaluating innovative maintenance therapies, including PARP inhibitors such as niraparib and olaparib, and investigating selective estrogen receptor degraders like elacestrant. Their clinical trial portfolio emphasizes biomarker-driven treatment selection, incorporating genetic testing for BRCA mutations and liquid biopsy techniques for ctDNA detection to optimize patient outcomes in ER+/HER2- breast cancer and advanced epithelial ovarian cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AGO Research GmbH1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis Dr. Pourfard & Dr. Uleer
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 2 | Unknown | 2022-06-24 | 2024-02-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.